French venture capital firm Sofinnova Partners has announced the closing of a $200 million fund, spearheaded by partners Edward Kliphuis and Simon Turner. 27 October 2023
As drugmakers around the world rush to embrace the potential of artificial intelligence (AI) in the design and development of new medications, the World Health Organization has urged caution. 23 October 2023
A company founded by Flagship Pioneering, Generate Biomedicines, has raised over a quarter of a billion dollars in a series C financing round. 14 September 2023
A new report from British market research firm Deep Pharma Intelligence provides a profile of the use of artificial intelligence in the drug discovery industry. 17 August 2023
The European Medicines Agency (EMA) has published a draft reflection paper outlining the current thinking on the use of artificial intelligence (AI) to support the safe and effective development, regulation and use of medicines. 19 July 2023
Developing new drugs is a complex and expensive process with a high failure rate. In fact, only about one out of 250 preclinical compounds make it to FDA approval. With an average cost of $40,000 per patient in a phase three clinical trial, the financial impact of failure is staggering. 4 July 2023
French drugmaker Sanofi has placed a strong emphasis on the adoption of artificial intelligence capabilities to facilitate its internal operations. 13 June 2023
The life sciences industry has always been subjected to transparency requirements. To help avoid compliance violations that may lead to penalties, many life science organizations have ramped up their efforts to collect compliance data and streamline the reporting process. 10 May 2023
Roche has announced the launch of the Institute of Human Biology (IHB), focussing on advancing research in the field of human model systems such as organoids. 5 May 2023
US biotech success story Moderna has turned to one of the world’s leading tech companies as it seeks to stay at the forefront of advancing mRNA medicines. 21 April 2023
There have been huge changes in the way highly regulated markets operate in recent years – caused by new regulations, technologies and demands. 6 April 2023
It seems every other day we hear of a new cyberattack in the news and it’s clear that these attacks are becoming an ever-growing, global concern. 27 March 2023
Belgian drugmaker UCB has teamed up with US firm Aitia in an early drug discovery collaboration focused on the discovery and validation of new drug targets and candidates for Huntington’s disease. 15 March 2023
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
ZipBio, a newly launched start-up based in Seattle, USA, is aiming to set a new standard in the development of biologics and gene therapies by utilizing generative AI technology. 9 September 2024
Otsuka Pharmaceuticals says that its subsidiaries Otsuka Precision Health, Inc. (OPH) and Click Therapeutics (Click) have launched Rejoyn (developed as CT-152). 19 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
At a cool $1 billion, the venture round secured by AI group Xaira ranks as the second-biggest raise in biotech history. In the drug discovery space, this financing is dwarfed only by Altos Lab’s $3 billion, amassed back in 2021. 14 May 2024
The world’s top 20 pharma companies spent $145 billion between them on R&D investments in 2022-23 - compared to the prior year’s $139 million - according to research from the professional services firm Deloitte. 29 April 2024